Dasatinib and the Risk of Pulmonary Arterial Hypertension
October 21, 2011, 3:55 PM
Dasatinib and the Risk of Pulmonary Arterial Hypertension
In this podcast, Jennifer Shepherd, a pharmacist in the FDA’s Division of Drug Information, discusses the increased risk of pulmonary arterial hypertension associated with Sprycel (dasatinib), a drug indicated to treat leukemia.
To access the podcast, click here.
To access the podcast, click here.
Your comments are valuable to us. Thank you.

American Journal of Managed Care
American Journal of Pharmacy Benefits
HCPLive
ONCLive
OTCGuide
PainLive
Pharmacy Times
Physician's Money Digest
American Journal of Pharmacy Benefits
HCPLive
ONCLive
OTCGuide
PainLive
Pharmacy Times
Physician's Money Digest
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2011
Intellisphere, LLC. All Rights Reserved.
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2011
Intellisphere, LLC. All Rights Reserved.




Email
Print


